#RATIONALE301 - Twitter Hashtag

almost 4 years ago

2. #RATIONALE301 Ph3, 1L in unresectable HCC, tislelizumab (anti-PD1) vs Sorafenib - Non-inferior OS with Tisle vs. Sorafenib - mOS: 15.9mos vs 14.1mos - Atezo + Bev is still 1L SoC (or Tremelimumab plus Durvalumab? in very selected cases) 3/5

OncBrothers's tweet photo. 2. #RATIONALE301 Ph3, 1L in unresectable HCC, tislelizumab (anti-PD1) vs Sorafenib

- Non-inferior OS with Tisle vs. Sorafenib
- mOS: 15.9mos vs 14.1mos
- Atezo + Bev is still 1L SoC (or Tremelimumab plus Durvalumab? in very selected cases)

3/5 https://t.co/SXBtMCgfYI

1

2

0

Oncology Brothers

@OncBrothers

almost 4 years ago

Day 2 #ESMO22 Highlights #CommunityOncology 1. #LEAP002 - HCC shared by @GillSharlene 2. #RATIONALE301 - HCC shared by @ArndtVogel 3. #ADAPTET - adj breast CA shared by @ErikaHamilton9 4. #IMMotion010 - adj RCC by @montypal @myESMO #MedTwitter #GUSM #GISM #bcsm 1/5

1

64

35

11

0

Cissa Mathias @cissamathias

almost 4 years ago

#esmo2022 Hot off the press! 📌📰 So what have we learned from the HCC LBAs? 🤓🤔 Advanced disease patients have an improved OS on TKIs alone (Lenvatinibe w/ best seen yet OS curve!) and combination therapies are a thing and should stay that way! #LEAP-002 #RATIONALE301

1

16

1

0

Lorenza Rimassa @LorenzaRimassa

almost 4 years ago

What a session! A packed room for three first-line phase 3 trials of #Immunotherapy for #HCC #LEAP002 #RATIONALE301 and #CamrelizumabApatinib at #ESMO22 @myESMO @DrAngelaLamarca @StephenLChan1 #KatieKelley #RichardFinn

LorenzaRimassa's tweet photo. What a session! A packed room for three first-line phase 3 trials of #Immunotherapy for #HCC #LEAP002 #RATIONALE301 and #CamrelizumabApatinib at #ESMO22 @myESMO @DrAngelaLamarca @StephenLChan1 #KatieKelley #RichardFinn https://t.co/dBCS9IZndG

1

33

11

1

0

HCC CONNECT powered by COR2ED

@hccconnectinfo

almost 4 years ago

#ILCA2022, Systemic therapy guidance talk ongoing with Tim Meyer & Robin Kate Kelley. Important clinical practice questions to address with recent/upcoming results from Phase 3 trials: #COSMIC312, #HIMALAYA, #LEAP002, #RATIONALE301 & Camrelizumab+rivoceranib in 1L #HCC #MedEd

hccconnectinfo's tweet photo. #ILCA2022, Systemic therapy guidance talk ongoing with Tim Meyer & Robin Kate Kelley.
Important clinical practice questions to address with recent/upcoming results from Phase 3 trials: #COSMIC312, #HIMALAYA, #LEAP002, #RATIONALE301 & Camrelizumab+rivoceranib in 1L #HCC #MedEd https://t.co/emqyqQQOzl

1

5

1

0

ScienceLink

@sciencelinkonco

about 4 years ago

#Tislelizumab #RATIONALE301 #ScienceLink HCC no resecable: Tislelizumab en 1L cumplió su objetivo primario de SG no inferior, estudio RATIONALE 301 https://t.co/BHVAlzPF95

sciencelinkonco's tweet photo. #Tislelizumab #RATIONALE301 #ScienceLink
HCC no resecable: Tislelizumab en 1L cumplió su objetivo primario de SG no inferior, estudio RATIONALE 301
https://t.co/BHVAlzPF95 https://t.co/aEcSQpEEhi

0

2

1

0

Top Tweets for #RATIONALE301

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users